NCT07179380

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

← Hub

Registry fields

Overall status: RECRUITING
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo
Lead sponsor: Insmed Incorporated (INDUSTRY)

Cached at: 2026-08-15 01:19:05

View on ClinicalTrials.gov

Brief summary

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report